But studies consistently show that, despite their elevated need, racial minorities receive significantly fewer prescriptions for GLP-1s. Oprah Winfrey, whose battles with weight loss are well-documented, hosted a highly publicized ABC special on GLP-1s in 2024. The lower adoption of GLP-1s by racial minorities has been, ironically, largely of Big Pharma’s making. A review of clinical trials conducted with GLP-1s found that Black and Latino people were significantly underrepresented relative to white people. Despite outcry, Medi-Cal severed coverage of GLP-1s for weight loss earlier this year as part of a broader budget-trimming effort in California.